The Burden of Major Adverse Cardiac Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease. Issue 2 (3rd March 2016)

• Record Type: Journal Article
• Authors: Khoury, Hanane; Lavoie, Louis; Welner, Sharon; Folkerts, Kerstin
• Is Part Of: Cardiovascular therapeutics. Volume 34:Issue 2(2016:Apr.)
• Page Start: 115
• Page End: 124
• Publication Date: 2016-03-03
• Subjects: Adverse cardiac events -- Anticoagulation -- Coronary artery disease -- Peripheral arterial disease -- Secondary prevention; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals; Cardiovascular Agents -- Periodicals; Cardiovascular Diseases -- drug therapy -- Periodicals; Agents cardiovasculaires -- Périodiques; Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques; 616.1005
• DOI: 10.1111/1755-5922.12169
• Languages: English
• ISSNs: 1755-5914

Abstract

Summary: Background: Patients with a history of a cardiovascular (CV) disease are at high risk of suffering secondary major adverse cardiac events (MACE), namely death, nonfatal myocardial infarction (MI), stroke, symptomatic pulmonary embolism, CV and all‐cause hospitalization, and bleeding. Methods: A comprehensive review of the literature was conducted to review the epidemiology and burden of MACE in patients with coronary or peripheral arterial disease (CAD or PAD) in Europe and other ex‐US regions. Relevant articles published between 2003 and 2013 were retrieved from PubMed and other sites. Results: MACE incidence and prevalence in patients with CAD or PAD were increased by at least 1.4‐fold compared with matched controls with no CV disease. In patients with CAD, MACE mostly occurred within 30 days of primary percutaneous coronary intervention; incidence decreased with time. Increased oxidative stress in coronary and peripheral arteries, diabetes, and chronic kidney disease were identified as the main risk factors for MACE in patients with CAD and PAD. Registry data showed that, although preventive antiplatelet therapy was prescribed at high rates, a large proportion (9–56%) of patients did not receive treatment. Furthermore, adherence to treatment declined over time, potentially leading to disease worsening. Conclusion: Despite gaps in the literature, this assessment showed that MACE's risk is substantial among patients with CAD or PAD and that the use of preventive therapies is suboptimal. Development of additional preventive therapies for these patients is warranted.